To explore the therapeutic effect of fenofibrate combined with dapagliflozin in the treatment of diabetic nephropathy(DN).
This study was a prospective randomized controlled trial. 500 patients with DN who admitted to the department of nephrology, Hebei hepatopathy hospital of traditional Chinese medicine from January 2021 to January 2024 were selected and randomly divided into the control group and the observation group, with 250 cases in each group. The control group was treated with dapagliflozin orally, while the observation group was treated with fenofibrate in addition to the treatment of the control group. Both groups were treated continuously for 12 months. The primary endpoint was the renal composite hard endpoint[defined as a declinein estimated glomerular filtration rate(eGFR)of ≥40% or progression to end-stage renal disease] at 12 months of treatment, and the secondary endpoints included differences in blood glucose indicators, renal function indicators, inflammatory factors, microcirculation indicators,oxidative stress indicators before treatment, at 6 and 12 months of treatment, as well as safety comparisons.
After 12 months of follow-up, the incidence of the renal composite hard endpoint in the observation group was lower than that in the control group(P<0.05). At 6 and 12 months, the fasting blood glucose, glycosylated hemoglobin, serum creatinine,24-hour urinary microprotein excretion rate, β2 microglobulin, C-reactive protein, interleukin-6, endothelin-1, fibrinogen,whole blood low shear viscosity, malondialdehyde in the observation group were lower than those in the control group,while the superoxide dismutase and glutathione peroxidase were higher than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).
Fenofibrate combined with dapagliflozin can significantly reduce the risk of the renal composite hard endpoint in patients with DN, demonstrating a clear long-term renal protective effect. It may achieve this through multiple pathways such as synergistically regulating blood glucose, protecting renal function, inhibiting the systemic inflammation, improving microcirculation, and reducing oxidative stress damage. Moreover, it does not increase adverse reactions, with good safety.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |